XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Convertible Senior Notes Due 2022
Common Stock
Common Stock
Convertible Senior Notes Due 2022
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Additional Paid-In Capital
Convertible Senior Notes Due 2022
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
 [1]
Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021       44,734,000              
Balance at beginning of period at Dec. 31, 2021 $ 730,408 $ (49,233)   $ 45   $ 942,091 $ (96,468)   $ (211,895) $ 47,235 $ 167
Increase (Decrease) in Stockholders' Equity                      
Exercise of stock options (in shares)       630,000              
Exercise of stock options 21,935     $ 1   21,934          
Vested restricted stock units (in shares)       299,000              
Common stock issued under employee stock purchase plan (in shares)       37,000              
Common stock issued under employee stock purchase plan 1,821         1,821          
Stock-based compensation 22,733         22,733          
Issuance of common stock upon conversion of 2022 convertible senior notes (in shares)         102,000            
Issuance of common stock upon conversion of 2022 convertible senior notes     $ 3,040         $ 3,040      
Other comprehensive income (loss) (772)                   (772)
Net income 26,704               26,704    
Ending balance (in shares) at Jun. 30, 2022       45,802,000              
Balance at ending of period at Jun. 30, 2022 756,636     $ 46   895,151     (137,956)   (605)
Beginning balance (in shares) at Mar. 31, 2022       45,064,000              
Balance at beginning of period at Mar. 31, 2022 709,576     $ 45   867,890     (157,832)   (527)
Increase (Decrease) in Stockholders' Equity                      
Exercise of stock options (in shares)       307,000              
Exercise of stock options 10,857     $ 1   10,856          
Vested restricted stock units (in shares)       292,000              
Common stock issued under employee stock purchase plan (in shares)       37,000              
Common stock issued under employee stock purchase plan 1,821         1,821          
Stock-based compensation 11,544         11,544          
Issuance of common stock upon conversion of 2022 convertible senior notes (in shares)         102,000            
Issuance of common stock upon conversion of 2022 convertible senior notes     $ 3,040         $ 3,040      
Other comprehensive income (loss) (78)                   (78)
Net income 19,876               19,876    
Ending balance (in shares) at Jun. 30, 2022       45,802,000              
Balance at ending of period at Jun. 30, 2022 756,636     $ 46   895,151     (137,956)   (605)
Beginning balance (in shares) at Dec. 31, 2022       45,928,000              
Balance at beginning of period at Dec. 31, 2022 $ 775,010     $ 46   924,095     (148,751)   (380)
Increase (Decrease) in Stockholders' Equity                      
Exercise of stock options (in shares) 61,896     62,000              
Exercise of stock options $ 1,914         1,914          
Vested restricted stock units (in shares)       369,000              
Common stock issued under employee stock purchase plan (in shares) 50,634     50,000              
Common stock issued under employee stock purchase plan $ 1,672         1,672          
Stock-based compensation 22,945         22,945          
Other comprehensive income (loss) 207                   207
Net income 6,227               6,227    
Ending balance (in shares) at Jun. 30, 2023       46,409,000              
Balance at ending of period at Jun. 30, 2023 807,975     $ 46   950,626     (142,524)   (173)
Beginning balance (in shares) at Mar. 31, 2023       45,970,000              
Balance at beginning of period at Mar. 31, 2023 768,041     $ 46   936,419     (168,287)   (137)
Increase (Decrease) in Stockholders' Equity                      
Exercise of stock options (in shares)       50,000              
Exercise of stock options 1,580         1,580          
Vested restricted stock units (in shares)       339,000              
Common stock issued under employee stock purchase plan (in shares)       50,000              
Common stock issued under employee stock purchase plan 1,672         1,672          
Stock-based compensation 10,955         10,955          
Other comprehensive income (loss) (36)                   (36)
Net income 25,763               25,763    
Ending balance (in shares) at Jun. 30, 2023       46,409,000              
Balance at ending of period at Jun. 30, 2023 $ 807,975     $ 46   $ 950,626     $ (142,524)   $ (173)
[1] Effective January 1, 2022, the Company adopted Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) on a modified retrospective method of transition. As a result, the Company no longer separately presents in equity an embedded conversion feature for its convertible debt.